TR200200438T2 - Pharmaceutical compositions containing thiazolidinedione derivatives and the process of preparing these compositions. - Google Patents

Pharmaceutical compositions containing thiazolidinedione derivatives and the process of preparing these compositions.

Info

Publication number
TR200200438T2
TR200200438T2 TR2002/00438T TR200200438T TR200200438T2 TR 200200438 T2 TR200200438 T2 TR 200200438T2 TR 2002/00438 T TR2002/00438 T TR 2002/00438T TR 200200438 T TR200200438 T TR 200200438T TR 200200438 T2 TR200200438 T2 TR 200200438T2
Authority
TR
Turkey
Prior art keywords
preparing
compositions
thiazolidinedione derivatives
pharmaceutical compositions
pharmaceutically acceptable
Prior art date
Application number
TR2002/00438T
Other languages
Turkish (tr)
Inventor
Edwin Buckingham Robin
Urquhart Michael
Original Assignee
Smithkline Beecham P.L.C.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9919465.6A external-priority patent/GB9919465D0/en
Priority claimed from GBGB9919842.6A external-priority patent/GB9919842D0/en
Priority claimed from GBGB9920149.3A external-priority patent/GB9920149D0/en
Application filed by Smithkline Beecham P.L.C. filed Critical Smithkline Beecham P.L.C.
Publication of TR200200438T2 publication Critical patent/TR200200438T2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A1'in OH veya -OSO2OH; R1'in bir hidrojen atomu veya bir C1-6 alkil grubu; ve R2 ve R3'ün her birinin hidrojen oldugu veya R2 ve R3'ün birlikte bir bag oldugu formül (I) etkin toksik olmayan miktarda bir bilesigi veya bunun bir tautomerik formunun ve/veya farmasötik olarak kabul edilebilir bir tuzunun ve/veya farmasötik olarak kabul edilebilir bir solvati ile farmasötik olarak kabul edilebilir bir tasiyiciyi içeren farmasötik bir terkip.A1 is OH or -OSO2OH; R1 is a hydrogen atom or a C1-6 alkyl group; and a compound of formula (I) in which R2 and R3 are each hydrogen or R2 and R3 are bonded together, or a tautomeric form and / or a pharmaceutically acceptable salt thereof and / or pharmaceutically acceptable. A pharmaceutical composition comprising a soluble solvate and a pharmaceutically acceptable carrier.

TR2002/00438T 1999-08-17 2000-08-14 Pharmaceutical compositions containing thiazolidinedione derivatives and the process of preparing these compositions. TR200200438T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9919465.6A GB9919465D0 (en) 1999-08-17 1999-08-17 Novel compounds
GBGB9919842.6A GB9919842D0 (en) 1999-08-20 1999-08-20 Novel compounds
GBGB9920149.3A GB9920149D0 (en) 1999-08-25 1999-08-25 Novel compounds

Publications (1)

Publication Number Publication Date
TR200200438T2 true TR200200438T2 (en) 2002-05-21

Family

ID=27269792

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2002/00438T TR200200438T2 (en) 1999-08-17 2000-08-14 Pharmaceutical compositions containing thiazolidinedione derivatives and the process of preparing these compositions.

Country Status (15)

Country Link
EP (1) EP1202991A1 (en)
JP (1) JP2003507379A (en)
KR (1) KR20020022812A (en)
CN (1) CN1379776A (en)
AU (1) AU7408900A (en)
BR (1) BR0013375A (en)
CA (1) CA2381976A1 (en)
CZ (1) CZ2002531A3 (en)
HU (1) HUP0202438A2 (en)
IL (1) IL148164A0 (en)
MX (1) MXPA02001716A (en)
NO (1) NO20020777D0 (en)
PL (1) PL353886A1 (en)
TR (1) TR200200438T2 (en)
WO (1) WO2001012628A1 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1284291A4 (en) * 2000-05-25 2005-06-08 Yamanouchi Pharma Co Ltd Human pgc-1 promoter
WO2003029251A1 (en) * 2001-09-28 2003-04-10 Biocon Limited Novel process for the synthesis of thiazolidinedione derivatives
GB0129871D0 (en) * 2001-12-13 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
GB0130509D0 (en) * 2001-12-20 2002-02-06 Smithkline Beecham Plc Novel pharmaceutical
KR100450700B1 (en) * 2002-03-22 2004-10-01 주식회사종근당 Thiazolidinedione derivatives and pharmaceutical composition comprising the same
KR20050068860A (en) 2003-12-30 2005-07-05 엘지.필립스 엘시디 주식회사 Upper substrate for use in dual-plate organic electroluminescent device and method for fabricating the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199003I1 (en) * 1987-09-04 2003-06-12 Beecham Group Plc Substituted thiazolidine ion derivatives
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
MX9603338A (en) * 1994-02-10 1997-03-29 Smithkline Beecham Plc Use of insulin sensitisers for treating renal diseases.

Also Published As

Publication number Publication date
MXPA02001716A (en) 2002-08-06
WO2001012628A1 (en) 2001-02-22
NO20020777L (en) 2002-02-15
BR0013375A (en) 2002-07-23
PL353886A1 (en) 2003-12-01
CN1379776A (en) 2002-11-13
CZ2002531A3 (en) 2002-07-17
HUP0202438A2 (en) 2002-12-28
CA2381976A1 (en) 2001-02-22
KR20020022812A (en) 2002-03-27
IL148164A0 (en) 2002-09-12
AU7408900A (en) 2001-03-13
NO20020777D0 (en) 2002-02-15
EP1202991A1 (en) 2002-05-08
JP2003507379A (en) 2003-02-25

Similar Documents

Publication Publication Date Title
DE60003001D1 (en) Pyrimidinverbindungen
CA2257016A1 (en) Imidazolidin-4-one derivatives useful as anticancer agents
NZ238424A (en) 3,5-substituted indole derivatives; medicaments and preparatory processes.
MY118904A (en) 4-oxo-1, 4-dihydro-3-quinolinecarboxamides as antiviral agents
ES482134A1 (en) 1-(3-Mercapto-2-methylpropanoyl)prolyl amino acid derivatives and salts thereof, processes for their preparation, and pharmaceutical compositions containing such compounds.
CA2328780A1 (en) Dihydropyrimidines
TW358808B (en) Morpholine derivatives, preparation thereof and pharmaceutical composition containing the same
CA2234096A1 (en) 1-(1,2-disubstituted piperidinyl)-4-substituted piperazine derivatives
CA2011346A1 (en) 2-(1-piperazinyl)-4-phenylcycloalkanopyridine derivatives, processes for the production thereof, and pharmaceutical composition containing the same
HUP0102453A2 (en) Adenosine derivatives, their use and pharmaceutical compositions containing the compounds
CA2340701A1 (en) Oxindole derivatives as growth hormone releasers
TR200103395T2 (en) 13-methyl erythromycin derivatives.
IL145759A0 (en) Amine derivatives and pharmaceutical compositions containing the same
KR960701878A (en) Water-soluble camptothecin derivatives, process for their preparation and their use as antitumor agents
AP9801321A0 (en) 2-(4-aryl or heteroaryl-piperazin-1-ylmethyl)-h-indole derivatives.
IL136558A0 (en) Heterocyclic cytotoxic agents
NO158578C (en) ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 3,1-BENZOKSAZIN-2-ON DERIVATIVES.
TR200200438T2 (en) Pharmaceutical compositions containing thiazolidinedione derivatives and the process of preparing these compositions.
DE69101673D1 (en) N-Substituted alpha-mercaptoalkylamine derivatives, processes for their preparation and intermediate products, their use as medicaments and compositions containing them.
TW200500369A (en) Cephem compounds
TR199902019T2 (en) �kame edilmi� thiazolidion' un haz�rlanmas� i�in proses.
PT1226122E (en) VASOPRESSIN BICYCLING AGONISTS
NZ238033A (en) 1-indanone- or 1-tetralone-2'-amidinohydrazone derivatives and pharmaceutical compositions thereof
HUP9701479A2 (en) N-benzylazolium derivatives containing hydrolysing group, process for their preparation and pharmaceutical compositions containing them
HUP9901969A2 (en) Use of n-mercaptoalkanoyl-cysteine derivatives for the preparation of pharmaceutical compositions traiting ischemia